An active immunotherapy called Provenge (sipuleucel-T) was approved in 2010 to treat advanced prostate cancer and its approval was due, in part, to the positive results of the IMPACT trial. Recently a commentary about the IMPACT trial was published in the Journal of the National Cancer Institute, which suggested that the placebo arm of the phase III trial did worse than expected due to immunodepletion, thus boosting the results of the Provenge arm.
Dr. Paul Schellhammer, one of the investigators on the IMPACT trial, joins us to respond to the study’s critique and explain why he feels that the criticism does not “pan out biologically and practically.”
Paul F. Schellhammer, MD
Program Director, Virginia Prostate Center, Eastern Virginia Medical SchoolDr. Paul F. Schellhammer is the program director of the Virginia Prostate Center and professor of urology at Eastern Virginia Medical School. Dr. Schellhammer earned his undergraduate degree at the University of Notre Dame in 1962 and graduated from Cornell Medical College in 1966. He completed a surgical internship and a surgical residency at University Hospitals of Cleveland in Ohio,... more >